Indaptus Therapeutics is trading $1.29 (-6.52%) after a sharp 46.81% advance to $1.38 on August 20.
- No major August 21 company announcement or overnight catalyst was identified.
- Recent Q2 results were released August 13, while a resale prospectus was filed August 17.
- The decline is not clearly explained by broader markets, which were modestly higher pre-market; volatility and profit-taking remain possible but unconfirmed.